INCLUSION CRITERIA: Diagnosis of CLL, FL, MCL, MZL, NHL NOS or WM  Must fulfil one of the following criteria to be enrolled in one study arm per vaccine received:  Patients with CLL AND one of the following:  i. Arm 1: Must be treatment naive (no prior cancer directed therapy)  ii. Arm 2: Patients that have received prior cancer directed therapy and are currently not receiving active treatment  iii. Arm 3: Must be receiving treatment with a BTKi. This arm is not available to patients receiving the HEPLISAV-B vaccine  iv. Arm 4: Must be receiving treatment with a BTKi for >= 6 months prior to vaccination and be willing to hold their treatment for up to 7 weeks around the time of each vaccination  v. Arm 5: Must be receiving treatment with a BCL-2 inhibitor  Or  Patients with FL AND one of the following:  i. Arm 1: Must be treatment naive (no prior cancer directed therapy)  ii. Arm 2: Must be receiving treatment with targeted therapies (e.g. BTKi, BCL-2 inhibitors, PI3K inhibitors, immunomodulatory agents, proteasome inhibitors)  Or  Patients with MCL, MZL, NHL NOS or WM AND one of the following:  i. Arm 1: Must be treatment naive (no prior cancer directed therapy)  ii. Arm 2: Must be receiving treatment with targeted therapies (e.g. BTKi, BCL-2 inhibitors, PI3K inhibitors, immunomodulatory agents)  If prior exposure to Hepatitis-B vaccination, must have documentation of negative serologic response Age >= 18 years Able to comprehend the investigational nature of the protocol and provide informed consent  EXCLUSION CRITERIA:  Female patients who are currently pregnant History of severe allergic reaction to vaccines Concomitant inherited immunodeficiency Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator s opinion, could compromise the subject s safety or put the study outcomes at undue risk. Receive cytotoxic chemotherapy within 2 weeks prior to vaccination Receive intravenous immunoglobulin (IVIG) within 2 months prior to vaccination Receive anti-CD20 and/or anti-CD19 monoclonal antibody therapy within 6 months prior to vaccination Receive cellular therapy (e.g. CAR-T cells) within 12 months prior to vaccination History of allogeneic stem cell transplantation